Trends and Challenges in Modeling Glioma Using 3D Human Brain Organoids

Overview

Journal Cell Death Differ

Specialty Cell Biology

Date 2020 Dec 2

PMID 33262470

Citations 24

Authors

Aruljothi Mariappan

Gladiola Goranci-Buzhala

Lucia Ricci-Vitiani

Roberto Pallini

Jay Gopalakrishnan

Affiliations

Soon will be listed here.

Abstract

The human brain organoids derived from pluripotent cells are a new class of three-dimensional tissue systems that recapitulates several neural epithelial aspects. Brain organoids have already helped efficient modeling of crucial elements of brain development and disorders. Brain organoids' suitability in modeling glioma has started to emerge, offering another usefulness of brain organoids in disease modeling. Although the current state-of-the organoids mostly reflect the immature state of the brain, with their vast cell diversity, human brain-like cytoarchitecture, feasibility in culturing, handling, imaging, and tractability can offer enormous potential in reflecting the glioma invasion, integration, and interaction with different neuronal cell types. Here, we summarize the current trend of employing brain organoids in glioma modeling and discuss the immediate challenges. Solving them might lay a foundation for using brain organoids as a pre-clinical 3D substrate to dissect the glioma invasion mechanisms in detail.

Citing Articles

Advancing Glioblastoma Research with Innovative Brain Organoid-Based Models.

Correia C, Calado S, Matos A, Esteves F, De Sousa-Coelho A, Campinho M Cells. 2025; 14(4).

PMID: 39996764 PMC: 11854129. DOI: 10.3390/cells14040292.

Enhanced Cytotoxic Effects of Cold Plasma Deposition of Topotecan: A Novel Approach for Local Cancer Drug Delivery to Glioblastoma Cells.

Pinheiro Lopes B, ONeill L, Bourke P, Boehm D Cancers (Basel). 2025; 17(2).

PMID: 39857983 PMC: 11764045. DOI: 10.3390/cancers17020201.

Advancing Alzheimer's Disease Modelling by Developing a Refined Biomimetic Brain Microenvironment for Facilitating High-Throughput Screening of Pharmacological Treatment Strategies.

Mohd Murshid N, Mohd Sahardi N, Makpol S Int J Mol Sci. 2025; 26(1.

PMID: 39796097 PMC: 11719782. DOI: 10.3390/ijms26010241.

Cell-Based Glioma Models for Anticancer Drug Screening: From Conventional Adherent Cell Cultures to Tumor-Specific Three-Dimensional Constructs.

Lanskikh D, Kuziakova O, Baklanov I, Penkova A, Doroshenko V, Buriak I Cells. 2025; 13(24.

PMID: 39768176 PMC: 11674823. DOI: 10.3390/cells13242085.

Reliability of high-quantity human brain organoids for modeling microcephaly, glioma invasion and drug screening.

Ramani A, Pasquini G, Gerkau N, Jadhav V, Vinchure O, Altinisik N Nat Commun. 2024; 15(1):10703.

PMID: 39702477 PMC: 11659410. DOI: 10.1038/s41467-024-55226-6.

References

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

Burnet N, Lynch A, Jefferies S, Price S, Jones P, Antoun N . High grade glioma: imaging combined with pathological grade defines management and predicts prognosis. Radiother Oncol. 2007; 85(3):371-8. DOI: 10.1016/j.radonc.2007.10.008. View

Furnari F, Fenton T, Bachoo R, Mukasa A, Stommel J, Stegh A . Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007; 21(21):2683-710. DOI: 10.1101/gad.1596707. View

Buckner J . Factors influencing survival in high-grade gliomas. Semin Oncol. 2004; 30(6 Suppl 19):10-4. DOI: 10.1053/j.seminoncol.2003.11.031. View

Rusthoven C, Koshy M, Sher D . Radiation plus Temozolomide in Patients with Glioblastoma. N Engl J Med. 2017; 376(22):2195-2197. DOI: 10.1056/NEJMc1704726. View

Swartling F, Cancer M, Frantz A, Weishaupt H, Persson A . Deregulated proliferation and differentiation in brain tumors. Cell Tissue Res. 2014; 359(1):225-54. PMC: 4286433. DOI: 10.1007/s00441-014-2046-y. View

Alcantara Llaguno S, Xie X, Parada L . Cell of Origin and Cancer Stem Cells in Tumor Suppressor Mouse Models of Glioblastoma. Cold Spring Harb Symp Quant Biol. 2016; 81:31-36. PMC: 6353557. DOI: 10.1101/sqb.2016.81.030973. View

DAlessandris Q, Biffoni M, Martini M, Runci D, Buccarelli M, Cenci T . The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response. Neuro Oncol. 2017; 19(8):1097-1108. PMC: 5737323. DOI: 10.1093/neuonc/now304. View

Azzarelli R, Simons B, Philpott A . The developmental origin of brain tumours: a cellular and molecular framework. Development. 2018; 145(10). PMC: 6001369. DOI: 10.1242/dev.162693. View

10.

Hakes A, Brand A . Neural stem cell dynamics: the development of brain tumours. Curr Opin Cell Biol. 2019; 60:131-138. DOI: 10.1016/j.ceb.2019.06.001. View

11.

Zanders E, Svensson F, Bailey D . Therapy for glioblastoma: is it working?. Drug Discov Today. 2019; 24(5):1193-1201. DOI: 10.1016/j.drudis.2019.03.008. View

12.

Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S . Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004; 64(19):7011-21. DOI: 10.1158/0008-5472.CAN-04-1364. View

13.

Singh S, Hawkins C, Clarke I, Squire J, Bayani J, Hide T . Identification of human brain tumour initiating cells. Nature. 2004; 432(7015):396-401. DOI: 10.1038/nature03128. View

14.

Pollard S, Yoshikawa K, Clarke I, Danovi D, Stricker S, Russell R . Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell. 2009; 4(6):568-80. DOI: 10.1016/j.stem.2009.03.014. View

15.

Bergmann N, Delbridge C, Gempt J, Feuchtinger A, Walch A, Schirmer L . The Intratumoral Heterogeneity Reflects the Intertumoral Subtypes of Glioblastoma Multiforme: A Regional Immunohistochemistry Analysis. Front Oncol. 2020; 10:494. PMC: 7193089. DOI: 10.3389/fonc.2020.00494. View

16.

Neftel C, Laffy J, Filbin M, Hara T, Shore M, Rahme G . An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell. 2019; 178(4):835-849.e21. PMC: 6703186. DOI: 10.1016/j.cell.2019.06.024. View

17.

Sottoriva A, Spiteri I, Piccirillo S, Touloumis A, Collins V, Marioni J . Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A. 2013; 110(10):4009-14. PMC: 3593922. DOI: 10.1073/pnas.1219747110. View

18.

Gerlinger M, Rowan A, Horswell S, Math M, Larkin J, Endesfelder D . Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10):883-892. PMC: 4878653. DOI: 10.1056/NEJMoa1113205. View

19.

Jacob F, Salinas R, Zhang D, Nguyen P, Schnoll J, Wong S . A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity. Cell. 2019; 180(1):188-204.e22. PMC: 7556703. DOI: 10.1016/j.cell.2019.11.036. View

20.

Hubert C, Rivera M, Spangler L, Wu Q, Mack S, Prager B . A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo. Cancer Res. 2016; 76(8):2465-77. PMC: 4873351. DOI: 10.1158/0008-5472.CAN-15-2402. View